Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares Acquired by Creative Planning

Creative Planning boosted its stake in Viking Therapeutics, Inc. (NASDAQ:VKTX) by 7.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,955 shares of the biotechnology company’s stock after acquiring an additional 1,202 shares during the period. Creative Planning’s holdings in Viking Therapeutics were worth $1,074,000 at the end of the most recent reporting period.

Other hedge funds also recently added to or reduced their stakes in the company. Exchange Traded Concepts LLC raised its stake in shares of Viking Therapeutics by 320.3% in the 3rd quarter. Exchange Traded Concepts LLC now owns 69,503 shares of the biotechnology company’s stock valued at $4,400,000 after purchasing an additional 52,968 shares in the last quarter. Sanders Morris Harris LLC acquired a new stake in Viking Therapeutics during the third quarter valued at approximately $317,000. Perpetual Ltd lifted its holdings in Viking Therapeutics by 55.4% during the 3rd quarter. Perpetual Ltd now owns 1,269,152 shares of the biotechnology company’s stock worth $80,350,000 after buying an additional 452,344 shares during the last quarter. CWM LLC grew its position in shares of Viking Therapeutics by 34.1% in the 3rd quarter. CWM LLC now owns 2,036 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 518 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in shares of Viking Therapeutics by 124.6% in the 3rd quarter. GAMMA Investing LLC now owns 438 shares of the biotechnology company’s stock valued at $28,000 after acquiring an additional 243 shares during the last quarter. 76.03% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. StockNews.com upgraded Viking Therapeutics to a “sell” rating in a research note on Tuesday, October 15th. JPMorgan Chase & Co. assumed coverage on shares of Viking Therapeutics in a research report on Wednesday, September 11th. They issued an “overweight” rating and a $80.00 price target on the stock. Raymond James increased their price objective on shares of Viking Therapeutics from $116.00 to $118.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 25th. Morgan Stanley restated an “overweight” rating and issued a $105.00 target price on shares of Viking Therapeutics in a research note on Thursday, September 12th. Finally, HC Wainwright reiterated a “buy” rating and set a $90.00 price target on shares of Viking Therapeutics in a research report on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $108.60.

Viking Therapeutics Price Performance

VKTX opened at $72.54 on Friday. The stock’s 50 day moving average price is $64.11 and its 200 day moving average price is $61.74. The stock has a market cap of $8.00 billion, a P/E ratio of -78.00 and a beta of 1.00. Viking Therapeutics, Inc. has a 12 month low of $9.32 and a 12 month high of $99.41.

Viking Therapeutics (NASDAQ:VKTX) last issued its quarterly earnings results on Wednesday, October 23rd. The biotechnology company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.02. During the same period last year, the business earned ($0.23) EPS. Equities analysts anticipate that Viking Therapeutics, Inc. will post -0.98 EPS for the current year.

Insider Buying and Selling at Viking Therapeutics

In other news, Director Sarah Kathryn Rouan sold 11,000 shares of the company’s stock in a transaction that occurred on Friday, October 25th. The shares were sold at an average price of $80.89, for a total value of $889,790.00. Following the completion of the sale, the director now directly owns 9,500 shares of the company’s stock, valued at approximately $768,455. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, Director Sarah Kathryn Rouan sold 11,000 shares of Viking Therapeutics stock in a transaction on Friday, October 25th. The stock was sold at an average price of $80.89, for a total transaction of $889,790.00. Following the transaction, the director now directly owns 9,500 shares in the company, valued at approximately $768,455. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director J Matthew Singleton sold 20,786 shares of the business’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $57.53, for a total value of $1,195,818.58. Following the completion of the sale, the director now directly owns 9,500 shares in the company, valued at $546,535. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 525,473 shares of company stock valued at $37,088,158. Company insiders own 4.70% of the company’s stock.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.